Strategies in the Treatment of AIDS and Related Diseases: The Lessons of Cancer Chemotherapy

References

• Barré-Sinoussi F, Chermann J C, Rey F. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868–871
   PubMed Web of Science ®Google Scholar
• Gallo R C, Salahuddin S Z, Popovic M. Frequent detection and isolation of cytopathic retroviruses (HTLV-m) from patients with AIDS and at risk for AIDS. Science 1984; 224: 500–503
   PubMed Web of Science ®Google Scholar
• Poiesz B J, Ruscetti F W, Gazdar A F. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci (USA) 1980; 77: 7415–7419
   PubMed Web of Science ®Google Scholar
• Nixon D F, Huet S, Rolhbard J. An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS 1990; 4: 841–845
   PubMed Web of Science ®Google Scholar
• De Cock K M, Porter A, Kouadio J. Rapid and specific diagnosis of HIV-1 and HIV-2 infections: an evaluation of testing strategies. AIDS 1990; 4: 875–878
   PubMed Web of Science ®Google Scholar
• Anderson R M, May R M. Epidemiological parameters of HTV transmission. Nature 1988; 333: 514–519
   PubMed Web of Science ®Google Scholar
• Aronow H A, Brew B J, Price R W. The management of the neurological complications of HIV infection and AIDS. AIDS 1988; 2: S151–S159
   PubMed Web of Science ®Google Scholar
• Price R W, Brew B, Sidtis J. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239: 586–593
   PubMed Web of Science ®Google Scholar
• Von Pirquet C. Das Verhalten der Kutanen Tuberculin-Reaktion während der Masern. Deutsche Medizinische Wochenschrift 1908; 34: 1297–1310
   Google Scholar
• Wainberg M A, Mills E L. Mechanisms of virus-induced immune suppression. Can Med Assoc J 1985; 132: 1261–1265
   PubMed Web of Science ®Google Scholar
• Matthews T J, Weinhold K J, Lyerly H K. Interaction between the human T-cell lymphotropic virus type HJB envelope glycoprotein gpl20 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci (USA) 1987; 84: 5424–5428
   PubMed Web of Science ®Google Scholar
• Maddon P J, Dalgleish A G, McDougal J S. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47: 333–348
   PubMed Web of Science ®Google Scholar
• Trunecker J A, Luke W, Karjaleinen K. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 1988; 331: 84–86
   PubMed Web of Science ®Google Scholar
• Deen K C, McDougal J S, Inacker R. Soluble CD4 form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988; 331: 82–84
   PubMed Web of Science ®Google Scholar
• Daar E S, Li X L, Moudgil T. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci (USA) 1990; 87: 6574–6578
   PubMed Web of Science ®Google Scholar
• Till M A, Zolla-Pazner S, Gorny M K. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci (USA) 1989; 86: 1987–1991
   PubMed Web of Science ®Google Scholar
• Ashorn P, Moss B, Weinstein. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CDA-Pseudonwnas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci (USA) 1990; 87: 8889–8893
   PubMed Web of Science ®Google Scholar
• Vitetta E S, Fulton R J, May R D. Redesigning nature's poison to create anti-tumor reagents. Science 1987; 238: 1098–1104
   PubMed Web of Science ®Google Scholar
• Smith T J, Kremer M J, Luo M. The site of attachment in human Rhinovirus 14 for antiviral agents that inhibit uncoating. Science 1986; 233: 1286–1293
   PubMed Web of Science ®Google Scholar
• Furman P A, Fyfe J A, Clair M H, St. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with HTV reverse transcriptase. Proc Natl Acad Sci (USA) 1986; 83: 8333–8337
   PubMed Web of Science ®Google Scholar
• Fischl M A, Richman D D, Causey D M. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989; 262: 2405–2410
   PubMed Web of Science ®Google Scholar
• Fischl M A, Richman D D, Grieco M H. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185–191
   PubMed Web of Science ®Google Scholar
• Spector S A, Kennedy C, McCutchan J A. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. J Infect Dis 1989; 159: 822–828
   PubMed Web of Science ®Google Scholar
• Yarchoan R, Broueps P, Spitzer A R. Response of human immunodeficiency virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987; 1: 132–135
   PubMed Web of Science ®Google Scholar
• Horwitz J P, Chua J, Noel M. Nucleosides. V. The monomesylates of l-(2-deoxy-beta-D-lyxofuranosyl) thymine. J Org Chem 1964; 276: 2076–2078
   Google Scholar
• Collier A C, Bozette S, Coombs R W. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323: 1015–1021
   PubMed Web of Science ®Google Scholar
• Perno C-F, Yarchoan R, Cooney D A. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′ 3′-dideoxy-thymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989; 169: 933–951
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Lotze M T, Muul L M. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Weil-Hillman G, Fisch P, Prieve A F. Lymphokine-activated killer activity induced by in vivo interleukin-2 therapy: predominant role for lymphocytes with increased expression of CD2 and Leul9 antigens but negative expression of CD16 antigens. Cancer Res 1989; 49: 3680–3688
   PubMed Web of Science ®Google Scholar
• Skowron G, Merigan T C. Alternating and intermittent regimens of zidovudine (3′-azido-3′-deoxythymidine) and dideoxycytidine (2′3′-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Am J Med 1990; 88: 30S–23S, (Suppl 5B)
   Google Scholar
• Bozzette S A, Richman D D. Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine. Am J Med 1990; 88: 24S–26S, (Suppl 5B)
   PubMed Web of Science ®Google Scholar
• Meng T-C, Fischl M A, Richman D D. AIDS Clinical Trials Group, phase I/II study of combination 2′-3′-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. Am J Med 1990; 88: 27S–30S, (Suppl 5B)
   PubMedGoogle Scholar
• Soudeyns H, Yao X-J, Gao Q. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991; 35: 1386
   PubMed Web of Science ®Google Scholar
• Pauwels R, Andries K, Desmyter J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (London) 1990; 343: 470–474
   PubMed Web of Science ®Google Scholar
• Merluzzi V J, Hargrave K D, Labadia M. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250: 1411–1413
   PubMed Web of Science ®Google Scholar
• Nakashima H, Balzarini J, Pauwels R. Anti-HIV-1 activity of antiviral compounds, as quantitated by a focal immunoassay in CD4-HeLa cells and a plaque assay in MT-4 cells. J Virol Methods 1990; 29: 197–208
   PubMed Web of Science ®Google Scholar
• Sandstrom E G, Byington R E, Kaplan J C. Inhibition of HTLV-III in vitro by phosphonoformate. Lancet 1985; 1: 1480–1482
   PubMed Web of Science ®Google Scholar
• Wainberg M A, Falutz J, Fanning M. Cessation of zidovudine therapy may lead to increased replication of HIV-1. JAMA 1989; 261: 865–866
   PubMed Web of Science ®Google Scholar
• Rooke R, Tremblay M, Wainberg M A. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology 1990; 176: 205–215
   PubMed Web of Science ®Google Scholar
• Mitsuya H, Yarchoan R, Broder S. Molecular target for AIDS therapy. Science 1990; 249: 1533–1544
   PubMed Web of Science ®Google Scholar
• Tan C-K, Civil R, Mian A M. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. Biochemistry 1991; 30: 4831–4835
   PubMed Web of Science ®Google Scholar
• Magnussen C R, Douglas R G, Ju R. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemo 1977; 12: 498–502
   PubMed Web of Science ®Google Scholar
• Vogt M W, Hartshorn K L, Furman P A. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235: 1376–1379
   PubMed Web of Science ®Google Scholar
• Holt J T, Redner R L, Nienhuis A W. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promonocytic cells and induces differentiation. Molec Cell Biol 1988; 8: 963–973
   PubMed Web of Science ®Google Scholar
• Zamecnik P C, Goodchild J, Taguchi Y, Sarin P S. Inhibition of replication and expression of human T-cell lymphotropic virus type IH in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci (USA) 1986; 83: 4143–4146
   PubMed Web of Science ®Google Scholar
• Renneisen K, Leserman L, Matthes E. Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. J Biol Chem 1990; 265: 16337–16342
   PubMed Web of Science ®Google Scholar
• Dryer G B, Metcalf B W, Tomaszek TA, Jr. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci (USA) 1989; 86: 9752–9756
   PubMed Web of Science ®Google Scholar
• Walker B D, Kowalski M, Goh W C. Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci (USA) 1987; 84: 8120–8124
   PubMed Web of Science ®Google Scholar
• Gruters R A, Neefjes J J, Tersmette M. Interference with HTV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 1987; 330: 74–77
   PubMed Web of Science ®Google Scholar
• Ruprecht R M, Bernard L D, Bronson R. Castanospermine vs its 6-O-butanoyl analog: a comparison of toxicity and antiviral activity in vitro and in vivo. J AIDS 1991; 4: 48–55
   PubMed Web of Science ®Google Scholar
• Walker B D, Chakrabarti S, Moss B. HrV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987; 328: 345–348
   PubMed Web of Science ®Google Scholar
• Gryllis C, Wainberg M A, Gornitsky M. Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders. AIDS 1990; 4: 1205–1212
   PubMed Web of Science ®Google Scholar
• Lifson J D, Reyes G R, McGrath M S. AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science 1986; 232: 1123–1127
   PubMed Web of Science ®Google Scholar
• Karpas A, Hill F, Youle M. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci (USA) 1988; 85: 9234–9237
   PubMed Web of Science ®Google Scholar
• Crumpacker C S, Schnktper L E, Marlowe S I. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 1982; 306: 343–346
   PubMed Web of Science ®Google Scholar
• Plotkin S A, Drew W L, Felsenstein D. Sensitivity of clinical isolates of human cytomegalovirus to 9-(l,3-dihydroxy-2-pro-poxymethyl)guanine. J Infect Dis 1985; 152: 833–834
   PubMed Web of Science ®Google Scholar
• Scholtissek C, Faulkner G P. Amartadine resistant and sensitive influenza A strains and recombinaits. J Gen Virol 1979; 44: 807–815
   PubMed Web of Science ®Google Scholar
• Larder B A, Darby G, Richman D D. HIV with reduced sensitivity to zidovudine(AZT) isolated during prolonged therapy. Science 1989; 243: 1731–1734
   PubMed Web of Science ®Google Scholar
• Rooke R, Tremblay M, Soudeyns H. Isolation of drug-resistant variants of HTV-1 from patients on long-term zidovudine therapy. AIDS 1989; 3: 411–415
   PubMed Web of Science ®Google Scholar
• Larder B A, Kemp S D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155–1158
   PubMed Web of Science ®Google Scholar
• Boucher C AB, Tersmette M, Lange J MA. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990; 2: 585–590
   Google Scholar
• Johnson V A, Barlow M A, Chou T-C. Synergistic inhibition of human immunodeficmecy virus type 1 (HTV-1) replication in vitro by recombinant soktble CD4 and 3′-azido-3′-deoxythymidine. J Inf Dis 1989; 159: 837–842
   PubMed Web of Science ®Google Scholar
• Dubreuil M, Sportza L, D'Addario M. Inhibition of HTV-1 transmission by interferon and 3′-azido-3′-deoxythymidine during de novo infection of promonocytic cells. Virology 1990; 179: 388–394
   PubMed Web of Science ®Google Scholar